title: Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
abstract: OBJECTIVE
  Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC). Gemcitabine-based combination chemotherapy has not yet shown promising results.
  
  
  METHODS
  This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma. Patients received 1,000 mg/m(2) gemcitabine, 100-min infusion, day 1 and 100 mg/m(2) oxaliplatin, 2-h infusion, day 2; q2w. The primary end point was response rate (RR).
  
  
  RESULTS
  Thirteen study centers enrolled 48 eligible patients of which 44 were evaluable. The RR, median overall survival, and median time to progression were 18.2%, 9.4 and 5.6 months, respectively. Sixteen patients (36.4%) experienced clinical benefit. The global quality of life scores improved by 11.71. Grade 3/4 peripheral sensory neuropathy was noted (2.1%), while the most common hematologic toxicity was anemia (grade 3/4, 6.3%).
  
  
  CONCLUSIONS
  Gemcitabine and oxaliplatin combination chemotherapy showed a promising activity in APC patients and was well tolerated.
authors.affiliation: Division of Hemato-Oncology, College of Medicine, Yeungnam University, Daegu, South Korea.
authors.forename: Kyung Hee
authors.initials: KH
authors.lastname: Lee
authors.forename: Min Kyoung
authors.initials: MK
authors.lastname: Kim
authors.forename: Yeol Hong
authors.initials: YH
authors.lastname: Kim
authors.forename: Baek Yeol
authors.initials: BY
authors.lastname: Ryoo
authors.forename: Ho Yeong
authors.initials: HY
authors.lastname: Lim
authors.forename: Hong Suk
authors.initials: HS
authors.lastname: Song
authors.forename: Hoon Kyo
authors.initials: HK
authors.lastname: Kim
authors.forename: Myung Ah
authors.initials: MA
authors.lastname: Lee
authors.forename: Seock Ah
authors.initials: SA
authors.lastname: Im
authors.forename: Heung Moon
authors.initials: HM
authors.lastname: Chang
authors.forename: Jae Yong
authors.initials: JY
authors.lastname: Cho
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Zang
authors.forename: Bong Seog
authors.initials: BS
authors.lastname: Kim
authors.forename: Jun Suk
authors.initials: JS
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D011788:Quality of Life; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000093542:Gemcitabine